All systems operational
Q3 2024

H syndrome: A histiocytosis-lymphadenopathy plus syndrome. A comprehensive review of the literature

Alaa Hamad · Hadeel Elwaheidi · Farah Salameh · Mossaed Alyahya · Riad El Fakih · Mahmoud Aljurf
10.4103/hemoncstem.hemoncstem-d-24-00004 390 Views 5 Citations
5
Citations
390
Views
Abstract

H syndrome is a rare autosomal recessive genodermatosis that falls under the histiocytosis-lymphadenopathy plus syndrome. The term “H syndrome” includes manifestations such as hyperpigmentation, hypertrichosis, hepatosplenomegaly, heart anomalies, hearing loss, hypogonadism, low height, and occasionally hyperglycemia. The syndrome is associated with mutations in the SLC29A3 gene, which encodes the human equilibrative transporter 3 present in endosomes, lysosomes, and mitochondria. The generalized and ubiquitous presence of affected lysosomes and mitochondria contributes to the systemic and phenotypically heterogeneous manifestations of the syndrome. H syndrome manifestations are cutaneous, systemic, and organ-specific. The pathognomonic signs are hypertrichosis and hyperpigmentation in the inner thighs and shins. However, not all patients present with these symptoms. H syndrome management involves a multidisciplinary approach to address specific symptoms and complications. The prognosis of H syndrome depends on several factors, including the extent and severity of clinical manifestations, the presence of complications, and timely diagnosis and management. Further studies are needed to explore the association between prognosis and the different mutations encountered in H syndrome.

Cite this Article (APA)
Alaa, H., Hadeel, E., Farah, S., Mossaed, A., Riad, E. F., Mahmoud, A. (2024). H syndrome: A histiocytosis-lymphadenopathy plus syndrome. A comprehensive review of the literature. Hematology/Oncology and Stem Cell Therapy. https://doi.org/10.4103/hemoncstem.hemoncstem-d-24-00004
Related Papers
The Risk and Prognosis of COVID-19 Infection in Cancer Patients
Ghada M. ElGohary; Shahrukh Hashmi; Jan Styczynski; Mohamed A. Kharfan-Dabaja; R · 2022
80
cites
396
Molecular mediators of breast cancer metastasis
Ragini Yeeravalli; Amitava Das · 2021
39
cites
386
Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia
Nosha Farhadfar; Ying Li; William S. May; Carolyn Brooke Adams · 2021
38
cites
389
Acute upper limb ischemia in a patient with COVID-19
Parminder Kaur; Firas Qaqa; Amr Ramahi; Yezin Shamoon; Monisha Singhal; Fayez Sh · 2021
35
cites
387
Access
View Full Text via DOI
Published in
ISSN 1658-3876
Quartile Q3
AMS Score 72
Field Medicine & Health Sciences
Publisher Elsevier / King Faisal Specialist H
Country 🇸🇦 Saudi Arabia
View Journal Profile →
Authors
Publication Details
Year 2024
Language English
Added 28 Jul 2026